Sponsor: 
Merck Sharp & Dohme (Australia)
Administration route: 
Intramuscular injection
Vaccine group: 
HPV vaccines

Registered for use in females aged 9 to <46 years and males aged 9 to <27 years.

9vHPV — Recombinant protein particulate (VLP) vaccine containing the major capsid (L1) protein of HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58

Each 0.5 mL monodose vial or pre-filled syringe contains:

  • 30 µg HPV-6 L1 protein
  • 40 µg HPV-11 L1 protein
  • 60 µg HPV-16 L1 protein
  • 40 µg HPV-18 L1 protein
  • 20 µg HPV-31 L1 protein
  • 20 µg HPV-33 L1 protein
  • 20 µg HPV-45 L1 protein
  • 20 µg HPV-52 L1 protein
  • 20 µg HPV-58 L1 protein
  • 0.78 mg L-histidine
  • 50 µg polysorbate 80
  • 35 µg sodium borate
  • residual traces (<7 µg) of yeast protein

All HPV proteins are adsorbed onto 500 µg of aluminium as aluminium hydroxyphosphate sulfate.

For detailed advice on vaccine dosage, administration, contraindications and precautions, please visit the relevant disease chapter.

Related diseases: 
Human papillomavirus (HPV)

Page history

Last updated: 
4 June 2018
Last reviewed: 
4 June 2018